{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '11. Suspected C1-INH resistance in the opinion of the investigator or sponsor.', '12. History of alcohol or drug abuse within the previous year prior to the screening visit, or', 'current evidence of substance dependence or abuse (self-reported alcoholic intake', '> 3 drinks/day).', '13. Positive serology for human immunodeficiency virus (HIV) or current infection with', 'hepatitis B virus (HBV) or hepatitis C virus (HCV).', '14. Pregnant or planning to become pregnant during the study.', '15. Currently breastfeeding. Women who want to enter the study must agree to suspend', 'breastfeeding at the screening visit. Women must wait at least 3 weeks after the last dose', 'of BCX7353 to commence breastfeeding.', '16. Positive drugs of abuse screen (unless drug is used as medical treatment with a', 'prescription).', '17. History of severe hypersensitivity to multiple medicinal products or severe', 'hypersensitivity/anaphylaxis with unclear etiology.', '18. Use of androgens or tranexamic acid for prophylaxis of angioedema events within the', '28 days prior to the screening visit or initiation during the study.', 'Prophylaxis is defined as administration of a medication in the absence of symptoms of', 'an angioedema event.', '19. Use of C1-INH for prophylaxis of angioedema events within the 14 days prior to the', 'screening visit or initiation during the study. Use of a C1-INH therapy for treatment of', 'angioedema events is not excluded at any time, nor is C1-INH for preprocedural', 'prophylaxis for an unplanned/unforeseer procedure.', 'Prophylaxis is defined as administration of a medication in the absence of symptoms of', 'an angioedema event.', '20. Use of concomitant medications that are metabolized by cytochrome P450 (CYP) 2D6,', 'CYP2C9, CYP2C19, and/or CYP3A4 and have a narrow therapeutic range, within 7 days', 'of the baseline visit or planned initiation during the study (see Section 9.7.1).', '21. Use of a medication that is clinically known to prolong the QT interval and is', 'metabolized by CYP2D6, CYP2C9, CYP2C19, and/or CYP3A4 7 days prior to the', 'baseline visit or planned initiation during the study (see Section 9.7.1).', '22. Use of a medication that is transported by P-glycoprotein (P-gp) and has a narrow', 'therapeutic range within 7 days of the baseline visit or planned initiation during the study', '(see Section 9.7.1).', '23. Use of an angiotensin-converting enzyme inhibitor within 7 days of the baseline visit or', 'planned initiation during the study.', '24. Initiation of an estrogen-containing hormonal contraceptive within 56 days of the', 'screening visit or planned initiation during the study. Established use (initiation > 56 days', 'prior to screening) during the study is permitted.', '45']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '25. Current participation in any other investigational drug study or received another', 'investigational drug within 30 days of the screening visit.', '26. An immediate family relationship to either sponsor employees, the investigator, or', 'employees of the study site named on the delegation log.', '27. Held in an institution by a government or judicial order.', '8.3.', 'Subject Withdrawal from the Study and from Study Drug', '8.3.1.', 'Subject Withdrawal from the Study', 'Participation in the study is strictly voluntary; a subject may withdraw consent to contribute', 'additional study information at any point. A subject who withdraws consent will be requested to', 'attend an early termination visit to complete all EOS evaluations. Although a subject may', 'withdraw from the study at any time without specifying a reason for withdrawal, the reason for', \"withdrawal, if provided by the subject, will be recorded in the subject's medical records (source\", 'documents) and also in the electronic case report form (eCRF). If the reason for subject', 'withdrawal is not known, the subject must be contacted to establish whether the reason was an', 'AE, and if so, this must be reported in accordance with the procedures outlined in Section 12.', 'If at any point in the study the clinic is unable to contact the subject after appropriate attempts', 'have been made, the subject will be considered lost to follow-up.', 'Once subjects have withdrawn from the study, the sponsor will no longer provide treatment', 'through the study. Following withdrawal from the study, a subject will be able to receive further', 'treatment as recommended by his or her treating physician and according to the accepted', 'standard of care.', '8.3.2.', 'Subject Discontinuation from Study Drug', 'A subject will be permanently discontinued from study drug for any of the following reasons,', 'which will be recorded in the source documents and eCRF.', 'Emergence of any laboratory abnormality or AE that in the judgment of the', 'investigator compromises the ability of the subject to continue study-specific', \"procedures or it is considered not to be in the subject's best interest due to an altered\", 'benefit-risk profile.', 'Reoccurrence of treatment-emergent AST or ALT elevation > 5 X ULN (confirmed)', 'if BCX7353 is restarted after meeting hold criteria as outlined in Section 12.2.2.', 'Treatment-emergent ALT or AST > 3 X ULN combined with either laboratory', \"abnormalities indicative of significant hepatic toxicity (ie, meeting Hy's law, total\", 'bilirubin > 2 X ULN OR with an international normalized ratio [INR] > 1.5) or with', 'symptomatology of acute hepatitis (ie, severe fatigue, nausea, vomiting, right upper', 'quadrant pain and tenderness, fever, rash, and/or eosinophilia P> 5%]).', 'Subsequent determination that inclusion/exclusion criteria were not met.', 'Intercurrent illness or emergence of a new illness/medical condition that would, in the', 'judgment of the investigator, affect assessments of clinical status to a significant', 'degree.', '46']\n\n###\n\n", "completion": "END"}